DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma

Cailing Yang1, Dapeng Wu, Jinling Jia

  • 1Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453100, China.

Insights

The tumor suppressor gene deleted in liver cancer-1 (DLC1) is downregulated in cutaneous squamous cell carcinoma (SCC), correlating with poorer patient survival and inhibited tumor progression. Restoring DLC1 levels suppressed proliferation and invasion in SCC cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • The tumor suppressor gene deleted in liver cancer-1 (DLC1) is frequently downregulated in various cancers.
  • The specific role and molecular mechanisms of DLC1 in cutaneous squamous cell carcinoma (cutaneous SCC) are not fully understood.

Purpose of the Study:

  • To investigate the role of DLC1 in the development and progression of cutaneous SCC.
  • To elucidate the molecular mechanisms underlying DLC1's function in cutaneous SCC.

Main Methods:

  • Quantified DLC1 expression levels in cutaneous SCC tissues and cells.
  • Overexpressed DLC1 in A431 cutaneous SCC cells.
  • Assessed the effects of DLC1 on cell proliferation, cell cycle, invasion, and apoptosis using Western blotting and activity assays.

Main Results:

  • DLC1 expression was significantly reduced in cutaneous SCC tissues, particularly in those with lymph node metastasis.
  • Lower DLC1 levels correlated with decreased patient survival rates.
  • DLC1 overexpression inhibited cell proliferation, induced G0/G1 cell cycle arrest, suppressed invasion, and promoted apoptosis in A431 cells.
  • DLC1 modulated the expression of key proteins involved in cell cycle regulation (p21, cyclin D1, cdk2), invasion (FAK, p-FAK, E-cadherin), and apoptosis (Bax, Bcl-2, caspase-3).

Conclusions:

  • DLC1 acts as a crucial tumor suppressor in cutaneous SCC.
  • DLC1 regulates key signaling pathways involved in proliferation, cell cycle, invasion, and apoptosis in cutaneous SCC.
  • DLC1 downregulation contributes to the development and progression of cutaneous SCC.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...